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Abstract. Members of the protein kinase C (PKC)
family are characterized by an NH2-terminal regulatory
domain containing binding sites for calcium, phospha-
tidylserine, and diacylglycerol (or tumor-promoting
phorbol esters), a small central hinge region and a
COOH-terminal catalytic domain . We have constructed
fusion proteins in which the regulatory domain of
PKCct was removed and replaced by a 19-amino acid
leader sequence containing a myristoylation consensus
or by the same sequence in which the amino-terminal
glycine was changed to alanine to prevent myristoyla-
tion. The goal was to generate constitutively active
mutants of PKC that were either membrane bound, due
to their myristoylation, or cytoplasmic. Western blot-
ting of fractions from COS cells transfected with plas-
mids encoding wild-type and mutant proteins revealed
that PKCci resided entirely in a Triton X-100 soluble
(TS) fraction, whereas both the myristoylated and
nonmyristoylated mutants were associated primarily
with the nuclear envelope fraction. A similar mutant
that lacked the 19 amino acid leader sequence was also
found almost entirely in the nuclear envelope, as was
P
ROTEIN kinase C alpha (PKCce)l belongs to a family
of serine/threonine protein kinases activated by cal-
cium, phospholipid, and the tumor promoting phor-
bol esters (Coussens et al ., 1986; Knopf et al., 1986). Mem-
bers of this family are characterized by an amino-terminal
regulatory domain containing co-factor-binding sites and a
carboxy-terminal catalytic domain (Bell and Burns, 1991;
Kikkawa et al ., 1989). A conserved pseudosubstrate se-
quence has also been identified in the regulatory domain,
near the extreme amino terminus (House and Kemp, 1987).
Current knowledge concerning the regulation of PKC
catalytic activity is consistent with a model in which the in-
active enzyme exists in a folded conformation, with the
amino-terminal pseudosubstrate sequence occupying the ac-
tive site (Bell and Burns, 1991; House and Kemp, 1987) .
Binding of cofactors to the regulatory domain is believed to
dislodge the pseudosubstrate sequence from the active site,
1. Abbreviations usedinthispaper: PDBu, phorbol dibutyrate; PKC, protein
kinase C; TI, Triton X-100 insoluble; TS, Triton X-100 soluble.
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a truncation mutant containing only the regulatory do-
main, hinge region, and a small portion of the catalytic
domain. However, an additional truncation mutant
consisting of only the regulatory domain plus the first
one-third of the hinge region was almost entirely in
the TS fraction . A nonmyristoylated fusion protein con-
taining only the catalytic domain was also found in
the nuclear envelope. Immunostaining of cells trans-
fected with these constructs revealed that both the
myristoylated and nonmyristoylated mutants were
localized in nuclei, whereas wild-type PKCcz was pri-
marily cytoplasmic and perinuclear. Phorbol
dibutyrate treatment of PKCa-transfected cells resulted
in increased perinuclear and nuclear staining. The
results are consistent with a model in which activation
of PKC, by phorbol esters or by deletion of the regula-
tory domain, exposes regions in the hinge and cata-
lytic domains that interact with a PKC "receptor" pres-
ent in the nuclear envelope, and may explain the
ability of wild-type PKC to be translocated to the nu-
cleus under certain conditions.
followed by intramolecular autophosphorylations which can
occur at three separate regions of the molecule, indicating
remarkable flexibility (Flint et al., 1990). This sequence of
events presumably leaves the enzyme membrane bound in an
active conformation, poised for interaction with the appro-
priate substrates. Previous models have envisioned binding
of activated PKC to membranes as being mediated by com-
plex interactions between the regulatory domain, cofactors,
and the membrane bilayer (Bell, 1986; Bell and Burns,
1991) .
Although the critical substrates for PKC have traditionally
been considered to be plasma membrane and cytoplasmic
proteins, Blackshear and co-workers (Halsey et al., 1987)
observed translocation ofPKC to the perinuclear region fol-
lowing treatment of 3T3-L1 fibroblasts with phorbol ester.
More recently, a PKCci-specific mAb revealed phorbol
ester-induced translocation of PKCct to the nuclear envelope
in NIH 3173 cells (Leach et al., 1989) . In HL60 cells, which
express PKCci and PKC,6,n, bryostatin treatment caused
selective translocation of PKC0 to the nuclear membrane
863(Hocevar and Fields, 1991). In rat embryo fibroblasts PKCa
was found to be associated with focal contacts in a nonionic
detergent- and chelator-resistant manner, suggesting that
PKC resides in the particular fraction due to protein-protein
as well as protein-lipid interactions (Jaken et al., 1989).
Consistent with this notion is the recent identification oftwo
proteins of 30 and 33 kD in a Triton X-100 insoluble (TI)
fraction (cytoskeleton plus nuclei) that interact specifically
and saturably with activated PKC (Mochly-Rosen et al.,
1991) . Binding of PKC to these "receptor" proteins was not
inhibitedby preincubation with a peptide substrate, implying
that this observation did not simply reflect an enzyme-sub-
strate recognition event and that the domain ofPKC involved
in the interaction lies outside the active site. The presence
of such receptors would explain the ability of activated PKC
to interact tightly with the detergent-insoluble fraction.
Prolonged treatment of cells with phorbol esters leads
to disappearance of immunoreactive PKC because of an
increased rate of proteolysis (Young et al ., 1987) . In vitro
proteolysis of purified PKC with trypsin or the calcium-
dependent protease calpain generates a lipid-binding regula-
tory domain and a constitutively active catalytic fragment
(PKM) that is no longer able to associate with membranes
(Lee and Bell, 1986; Melloni et al., 1985 ; Mizuta et al.,
1985). The site of proteolysis in vitro has been mapped to
a region of nonconserved sequence between the regulatory
and catalytic domains, referred to as the hingeregion (Kishi-
moto et al., 1989).
The ability to generate a constitutively active form ofPKC
in vitro ledto speculation thatthe phorbol ester-induced pro-
teolysis ofPKC in vivo might result in formation of a soluble
kinase (PKM) capable of phosphorylating cytoplasmic pro-
teins (Kikkawa et al ., 1989 ; Melloni et al., 1985; Mizuta
et al., 1985). Although calcium- and phospholipid-indepen-
dent kinase activity has been detected in cell extracts (Tapley
and Murray, 1984), numerous investigators have reported an
inability to detect the catalytic fragment of PKC by Western
blotting (presumably because of an extremely short half-
life), casting doubt on the physiological relevance of "PKM"
(Kikkawa et al ., 1989; Ways et al ., 1991). Thus, it remains
unclear whether the effects of chronic exposure to phorbol
esters are due to a reduced level of native PKC, continuous
generationofa constitutively active, yet short lived, catalytic
fragment, or some cellular process unrelated to PKC.
To distinguish amongthese possibilities and further define
theproperties ofthe PKC catalytic fragment in vivo, we con-
structed mutants of PKCce in which the regulatory domain
was removed and replaced by either a 19-amino acid leader
sequence containing a myristoylation consensus, or the same
sequence in which the amino-terminal glycine residue was
changed to alanine to prevent myristoylation. The myristoy-
lation consensus contains sufficient sequence information to
direct co-translational myristoylation (Wilcox et al., 1987)
and based on previous studies would be predicted to target
PKC to the níembrane fraction (see James and Olson, 1990
for review) . The goal was to generate constitutively active
PKC mutants that were either membrane bound, due to their
myristoylation, or cytoplasmic. Surprisingly, subcellular
fractionation oftransiently transfected COS cellsfollowed by
Western blotting revealed that both the myristoylated and
nonmyristoylated mutants were tightly associated with the
nuclear envelope fraction. Further deletion analyses re-
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vealed that at leasttwo segments, one in the hingeregion and
another in the catalytic domain, are responsible for nuclear
localization. These findings are consistent with a model in
which activation of PKC results in the unfolding ofthe mole-
cule and the exposure of regions in the hinge and catalytic
domains that have high affinity for one or more receptor pro-
teins present in the nuclear envelope. These observations
may explain the ability of PKC to be translocated to the nu-
cleus under certain conditions.
Materials and Methods
Cloning and Mutagenesis
SRcePKC, anexpression vectorcontaining a cDNAencoding bovine PKCa,
was obtained from Dr. Paul Simpson (University ofCalifornia at San Fran-
cisco, San Francisco, CA) (23). The murine MARCKS cDNA was cloned
fromanNIH 3T3 library using an oligonucleotidecorrespondingto a region
ofthe bovine MARCKS (80K) cDNA sequence (Stampo etal., 1989). The
first 19 amino acids ofthe murine andbovine MARCKS proteins are identi-
ca1.2 Site-directed mutagenesis, using a single-stranded template as de-
scribed (Brennan et al., 1991), wasused to change the second codon ofthis
cDNA, GGT (glycine), to GCC (alanine), thus preventing myristoylation
of the protein (Graff et al., 1989) .2 The mutation was confirmed by DNA
sequencing (Sequenase, United States Biochemical Corporation, Cleve-
land, OH). This mutantproteinwill bereferred to asAl, for alanineat posi-
tion 1 (following removal of the initiating methionine). A 220-bp fragment
from the 5' end of the MARCKS (80K) and Al cDNAs, encoding the first
19 amino acids of each protein, was subcloned into pUC19 between the
HindIII and BamHI sites. These plasmids were denoted 5'80K/pUC and
5Ál/pUC, and were used as cassettes into which various portions ofthe bo-
vine PKCa cDNA were inserted in-frame, resulting in myristoylated or
nonmyristoylated fusion proteins.
Forexpression in COS cells, all constructs were subclonedinto a deriva-
tive of pCDM8 (obtained from Dr. Randy Legerski, M.D. Anderson Can-
cer Center, Houston, TX), a vector in which expression is driven from the
cytomegalovirus promoter and which has the SV-40 origin of replication,
allowing amplification in COS cells (Seed, 1987). We constructed a deriva-
tive ofthis vector (pCDM8*) by removing the400-bp sequence between the
cytomegalovirus promoter andthe SV-40 polyadenylation signal and insert-
ing a portion ofthe pBluescript KS polylinker, fromthe HindIII to the Noll
sites, resulting in seven unique cloning sites.
PKCI and PKC2 wereconstructed by inserting a fragmentof ti2,100 bp,
extending from the NarI site at nucleotide 83 to the StUI site at nucleotide
2,180 in the 3'-untranslated region of the cDNA, into the Smal site of
5'80K/pUC and 5A1/pUC, respectively. The Narl site at the 5' end of the
fragment was blunt ended using Sl nuclease. Plasmids with inserts in the
correct orientation were identified by restriction mapping, and these were
sequencedto verify the reading frame. These constructs encode fusion pro-
teins in which the first 11 amino acids of PKCa have been deleted and
replaced by the first 19 amino acids of MARCKS or Al. PKCI and PKC8
were constructed using a 1,370-bp fragment extending from the Sacl site
at nucleotide 948 to the XbaI site at the 3'end ofthe cDNA. This fragment
was blunt ended with Sl nuclease and inserted into the BamHI site (blunt
ended with the Klenow fragmentof DNA polymerise I) of 5'80K/pUC and
5AI/pUC. Plasmidswith inserts in the correct orientationandreading frame
wereidentified as described above. These constructs encode fusion proteins
beginning at amino acid 302 ofPKCa. PKCA12-253 was made by excising
a 723-bp fragment between the Narl site at nucleotide 83 and the Xmnl site
at nucleotide 806. The 5' overhang at the Narl site was removed with S1
nuclease and the plasmid was religated. The correct reading was verified
by sequencing. PKC14 consists ofan 1,100-bp fragment extending from the
NcoI site at nucleotide 1201 to the 3' end of the cDNA. The 5' overhangs
on this fragment were filled and it was cloned into the BamHI site of
5A1/pUC, as described for PKC8. PKC16 was madeby inserting the 723-bp
XhoH fragment (blunt ended) from nucleotides 1,153 to 1,876 into the
BamHI site of 5AI/pUC, as described for PKC8. For PKCaTM385, the
1,152-bp Ncol fragment from nucleotides 49 to 1,201 was isolated, blunt
ended with Klenow, and cloned into the SmaI site of pCDM8! Plasmids
with inserts in the correct orientation were identified by restriction map-
2. James, G., and E. Olson, unpublished data.
864ping. PKCaTM310 was obtained by partial digestion to allow isolation of
an -1,000-bp fragment extending from a Hindill site in the pCDM8* poly-
linker to the HindlII site at nucleotide 975 ofthe PKCce cDNA. This frag-
ment was cloned into the HindIII site ofpCDM8*, and the orientation was
determined by restriction mapping. PKCTM385 and PKCTM310 have 36
and 43 amino acids, respectively, of non-PKC sequence at their carboxy-
termini derived from vector sequences on the 3' side of the cloning site.
In vitro transcription and translation was performed as described previ-
ously (Brennan et al., 1991).
CellCulture, MetabolicLabeling, and Tiransfections
Cells were maintained in DME containing 10% FBS, as described previ-
ously (James and Olson, 19ß9a).
For transient transfections, equal numbers COS-1 cells were seeded in
10-cm dishes (Falcon, Lincoln Park, NJ) at -50% confluency and were
transfected by calcium-phosphate precipitation 16-24 h after seeding, as
described (Sternberg et al., 1988). Cells were refed with medium contain-
ing 10% FBS 16 h after transfection, and were harvested 24-32 h later.
Metabolic labeling with [3Hjmyristate was performed as described pre-
viously (James and Olson, 1989a; Wilcox et al., 1987), with the label (0.5
mCi/10-cm dish) being added 8 h before harvesting.
SubcellularFractionation, SDS-PAGE,
and Western Blotting
Cells were harvested by scraping in PBS and collected by centrifugation,
as described (James and Olson, 1989a).
For preparation ofTriton X-100 soluble (TS) and TI fractions, cell pellets
were resuspended in 50 pl oflysis buffer A, consisting of 20 mM Tris HCI,
pH 7.5, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, and
protease inhibitors (0.5 mM PMSF, 5 pg/ml each of leupeptin, pepstatin,
and aprotinin). The suspension was vortexed, incubated on ice for 5 min,
and centrifuged for 30 s at 12,000 g. The supernatant was removed and
designated the TS fraction. Pellets (TI fraction) were washed once in lysis
buffer A and the wash was discarded. Protein concentrations were deter-
mined usingthe Coomassieprotein assay reagent from Pierce Chemical Co.
(Rockford, IL). SDS sample buffer was added to each fraction, samples
were boiled for 5 min and vortexed, and equal amounts were subjected to
SDS-PAGE as described (James and Olson, 19896).
Nuclear envelope and intranuclear protein fractions were prepared as de-
scribed by Kaufmann et al. (1983) . Lamin B and p38 chicken antisera were
obtained from Dr. Scott Kaufmann (Johns Hopkins Oncology Center (Balti-
more, MD) and have been described previously (Kaufmann, 1989; Fields
et al., 1986). These were detected using alkaline phosphatase-conjugated
rabbit anti-chicken IgG (Sigma Chemical Co., St. Louis, MO). Color de-
velopment was performed with nitro blue tetrazolium and 5-bromo-4-
chloro-3-indolyl phosphate (p-toluidine salt) according to the manufacturer's
instructions (Southern Biotechnology Associates, Inc., Birmingham, AL).
Proteins were transferred to nitrocellulose as described (James and Ol-
son, 19896). Blots were incubated with Blotto (James and Olson, 19896)
for 30 min to block unbound sites, and primary antibody (1:100 dilution in
Blotto) was added for 3-4 h. PKC antibodies used were either MC5, a mAb
(Amersham Corp., Arlington Heights, IL) whose epitope has been mapped
to amino acid residues 296-309 of PKCa (MC5 also recognizes PKC#),
or a PKCa-specific anti-catalytic domainmAb available from Upstate Bio-
technology, Inc. (Lake Placid, NY). A polyclonal antibody from Oncogene
Science, Inc. (Manhasset, NY) that recognizes amino acids 520-525 was
alsoused in some experiments. Blots were rinsed briefly and then incubated
with 1251-labeled goat anti-mouse or donkey anti-rabbit secondary anti-
body (Amersham Corp.) at 2 x 106 cpm/ml for 1-2 h. After being washed
for 15-30 min in Blotto, with several changes, blots were placed on film
for the indicated lengths of time.
Immunofluorescence
COS cells were seeded in 35-mm dishes and transfected with the indicated
plasmid as described above. 48 h after transfection, cells were rinsed with
PBS and fixed with an ice-cold mixture of acetone/ethanol (1:1) for 3 min.
After being rinsed with PBS, dishes were incubated for 30 min with PBS
containing 2% BSA. MC5 or anti-catalytic domain antibody, diluted 1:100
in PBS/1% BSA, was added for 2 h. Dishes were rinsed 3 x 5 min with
PBS/1% BSA, and fluorescein-conjugated goat anti-mouse secondary anti-
body (Sigma Chemical Co.) was added for 1 h at a dilutionof 1:100 in PBS/
1% BSA. Dishes were rinsed 3 x 5 min with PBS/1% BSA and 2 x 5 min
James and Olson Nuclear Targeting ofProtein Kinase C
with PBS. Immunostained cells were visualized at 495-nm wavelength and
photographed using Ektachrome 400 color film (Eastman Kodak Co.,
Rochester, NY).
ProteinKinase CAssays
Plasmids were transfected into COS cells in quadruplicate as described
above. PKC mutants were partially purified using a protocol similar to that
described by Housey et al. (1988). Cells were harvested after 48 h and cell
pellets were resuspended in 0.5 ml ofa buffer (lysis buffer B) consisting of
20 mM Tris HCl (pH 7.5), 5 mM EDTA, 5 mM EGTA, 15 mM 2-mercap-
toethanol, 0.1% Triton X-100, and protease inhibitors as described above.
Cells were disrupted by 50 strokes in a 1 nil Dounce homogenizer, and the
lysate was transferred to a 1.5-ml Eppendorf tube (Brinkmann Instruments
Inc., Westbury NY). The homogenizer was rinsed with 0.5 ml ofbuffer and
the rinse was added to the lysate. Lysates werecentrifuged 30s at 12,000 g,
and the supernatants were transferred to a fresh tube, diluted to 2 ml with
buffer, and applied to 0.4-ml DEAF Sephacel columns previously equil-
ibrated with lysis buffer B. Columns were washed with 20 vol of buffer B
and the PKC mutants were eluted with buffer B containing 200 mM NaCl.
Fractions were assayed for their ability to phosphorylate a peptide corre-
sponding in sequence to a region surrounding threonine 654 in the EGF
receptor, a site that is highly specific for PKC in vivo and in vitro (Housey
et al., 1988). Reactions were performed in the absence of cofactors, and
specific activities were calculated as describedin the protein kinase C assay
kit from Amersham Corp. All reagents used in the assays were from this
kit. Protein concentrations were determined as described above. Approxi-
mately 1% of each mutant protein was solubilized under these conditions
(see Results).
Results
Construction ofMyristoylatedandNonmyristoylated
PKCaMutants
Our initial aim was to compare the properties of a soluble
and membrane-bound PKC catalytic domain in vivo. We
therefore created fusion proteins in which the first 19 amino
acids of the murine MARCKS (80K) protein or of a non-
myristoylated mutant (Al) of this protein were fused in-
frame to various portions of PKCa. PKC1 and PKC2 consist
ofthe first 19 amino acids ofMARCKS and Al, respectively,
fused to amino acid 12 of PKCa (Fig. 1). These proteins
therefore retained the pseudosubstrate sequence, which lies
between amino acids 19 and 36 (House and Kemp, 1987).
These constructs were prepared as controls to test the effect
of myristoylation on the properties of full-length PKCa.
PKC7 (myristoylated) and PKC8 (nonmyristoylated) began
at residue 302, which is just beyond the end of conserved re-
gion C2, 12 amino acids into the hinge region.
The MARCKS protein is myristoylated at its amino-
terminal glycine residue, and a peptide consisting of the first
eight amino acids of this protein was previously shown to
serve as an efficient substrate for N-myristoyltransferase in
vitro (Graff et al., 1989). However, in certain cases, favora-
ble interactions between this enzyme and its substrates re-
quire structural information that lies beyond the first eight
residues (Duronio et al., 1991) . Thus, it was important to
verify that the first 19 amino acids of the MARCKS protein
were recognized by N-myristoyltransferase when present
outside of their normal context.
To study the properties ofthese mutants in vivo, constructs
were subcloned into a derivative of the expression vector
pCDM8 and transiently transfected into COS cells. PKCa
is the only PKC isoform knownto be expressed in these cells
(Ohno et al., 1990). Fig. 2 represents an experiment in
which PKCai, PKC1, PKC2, PKC7, and PKC8 were trans-
865fected into COS cells . The cells were labeled with ['H]
myristate for 8 h before harvesting, and equal amounts of
whole-cell lysates were then electrophoresed in duplicate .
Theproteins in onegelwere transferred to nitrocellulose and
analyzed by Western blotting withamAb(MC5) that recog-
nizes aminoacids296-309 ofPKCa . As shown in Fig. 2 a,
transfected PKCa, PKCI, and PKC2 co-migrated with en-
dogenous PKCu (ti77 kD) . PKC7 and PKC8 migrated at
-41 kD, consistent with their predicted molecular mass .
Only those fusion proteins with theMARCKS amino termi-
nus (PKCI and PKCI) were labeled with myristate (Fig . 2
b), indicating that the first 19 amino acids of the MARCKS
protein are sufficient to direct myristoylation in vivo .
Subcellular Distribution ofMyristoylated
and NonmyristoylatedMutants
Since the wild-type MARCKS protein is predominantly
membrane bound (James and Olson, 1989a) whereas the
nonmyristoylated mutant (Al) is almost entirely cytoplasmic
(Graff et al ., 1989), 2 PKC2 and PKC8 would be expected
to reside mainly in the cytoplasm . PKCI and PKC7 should
be able to associatewith membranes, at least to a certain ex-
tent, because of their myristoylation . Preliminary experi-
ments, however, indicated that PKCI and PKC8 were as-
sociated almost entirely with the 12,000 g nuclear pellet
following lysis of cells by freeze/thaw in hypotonic buffer
containing 1 mM EDTA andEGTA . PKCce andPKC2 were
foundpredominantly in the soluble (200,000g supernatant)
fraction . In contrast, PKCI was mostly in the crude mem-
brane (200,000-g pellet) fraction, presumably aresult of its
myristoylation (data not shown) .
We next prepared TS and TI fractions by fractionating
transfected COS cells in buffer containing EDTA, EGTA,
and 1% Triton X-100 . The TS fraction contains cytoplasmic
and peripheral plasma membrane proteins, whereas the TI
fraction consists primarily of cytoskeletal proteins and nu-
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Figure 1 . Diagram of wild-
type and mutant PKC con-
structs. The top bar shows the
domainorganizationofPKCa,
with the pseudosubstrate se-
quence (amino acids 19-36)
andhinge region (amino acids
290-336) also denoted . The
fusion proteins and deletion
mutants were constructed as
described in Materials and
Methods. Theblackbar at the
amino terminus of the fusion
proteinsindicates thepresence
of the first 19 amino acids of
theMARCKS (odd-numbered
constructs) or Al proteins
(even-numbered constructs) .
The myristate moiety isshown
diagrammatically attheendof
PKCI and PKCI. Subcellular
distributions were determined
by scanning densitometry of
theWestern blot shown in Fig .
3 . ND, not detectable.
clei (Ben-Ze'ev et al ., 1979) . Western blotting of these frac-
tions indicated thatPKCa, PKCI, andPKC2 were found en-
tirely in the TS fraction (Fig . 3) . Based on previous studies,
PKCce is expected to be completely solubleunder thesecon-
ditions (1 mM EDTA, 1 mM EGTA) . PKCI and PKC2 are
also expected to be soluble, sinceboth theMARCKS andAl
proteins are found entirely in the TS fraction following their
transfection into COS cells (data not shown) . In contrast,
>99% of PKCI and PKC8 were tightly associated with the
TI pellet (Fig . 3) andthey remained associated with this frac-
tion following extraction of the pellet with buffer containing
0.5 MNaCl (data not shown) . One interpretation of this re-
sult is that deletion of the regulatory domain exposes a re-
gion within thehinge or catalyticdomains that interacts with
some component of the cytoskeleton and/or nucleus.
To demonstrate that the subcellular localization observed
forPKC7 andPKC8 wasbecauseof aconformational change
in the hinge/catalytic domain and not to structural features
present in the MARCKS and Al amino termini, we con-
structed a mutant in which amino acids 12 to 253 were
deleted (PKCA12-253, seeFig . 1) . This mutant is missing a
large portion of the regulatory domain, including the pseu-
dosubstrate sequence,andwouldthereforebe expected to as-
sume a conformation similar to PKC7 and PKC8. However,
it contains thePKCof amino terminus insteadofthat from the
MARCKS or Al proteins . The distribution of PKCA12-253
was identical to that ofPKCI and PKC8 (Fig . 3), indicating
that the region responsible for localization of these mutants
to the TI fraction lies between amino acid 302 and the
COOH terminus . Additional mutants have revealed that de-
letion of as few as the first 186 amino acids from the PKCa
amino terminus is sufficient to induce distribution to the TI
fraction (data not shown) .
Previous in vitro studies have shown that proteolysis of
PKCby calpain occurs in thehingeregion, resulting inacon-
stitutively active catalytic fragment that is unable to associ-
ate with membranes (Kikkawa et al ., 1989) . Based on this
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Figure2 . Fusion proteins containing the MARCKS
aminoterminus are myristoylated . COS cells in 10-
cm dishes were transiently transfected with 15 Fig
each of plasmids encoding the indicated proteins
and labeled with [3H]myristate as described in Ma-
terials andMethods . Cell pellets were lysed in buffer
A, and equal amounts of total cell protein were
mixed withSDS sample buffer andelectrophoresed
in duplicate in 8% SDS-polyacrylamide gels (150
ug/lane) . The proteins in onegel were analyzed by
Western blotting (A) using the MC5 mAb and
115j
labeled goat anti-mouse secondary antibody (24-h
exposure). The other gel was treated with EN 3-
HANCE, dried, andplaced on film for 14d(B) . Po-
sitions of PKCa, PKCI, PKC2, and PKC7, and
PKC8 are indicated by the upper and lower arrows,
respectively. Migration of molecular weight stan-
dards is indicated at right.
Figure 3 Subcellular distribution of wild-type and
mutantPKCproteins . COS cells in 10-cm dishes were
transiently transfected with 15 ug each of plasmids
encoding theindicatedproteins .TS (S) andTI (I) frac-
tions were prepared as described in Materials and
Methods . The entire fractions, containing -150 (S)
and75 Wg (I) of protein each, were electrophoresed
in 10% SDS-polyacrylamide gels and analyzed by
Western blotting. PKC14was detected with a mixture
ofthe anti-catalytic domainmAbanda polyclonal an-
tibody recognizing amino acids 520-525, followed by
anti-mouse and anti-rabbit 125I-labeled secondary
antibodies . All other lanes were probed with MC5,
followed by anti-mouse '25I-labeled secondary anti-
body. Exposure times were 48 h except for PKC14
(24 h), PKCTM385, andPKCTM310(96 h) . Migra-
tion of molecular weight standards is indicated at
right . The distribution of all proteins wasanalyzed at
least twice, and in some cases up to 10 times, with
nearly identical results.information the region responsible for localization to the TI
fraction would be expected to be contained within the hinge
region, NH2-terminal to the catalytic domain. To address
this possibility, we constructed two truncation mutants,
PKCTM385 and PKCTM310, consisting ofthe first 385 and
first 310 amino acids of PKCa, respectively. As shown in
Fig. 3, PKCTM385 exhibited a distribution almost identical
to PKC7 and PKC8. PKCTM310, however, was found al-
most entirely in the IS fraction, suggesting that the region
between amino acids 310 and 385 mediates association with
the TI fraction . This region consists of approximately two-
thirds ofthe hingeregion and 49 amino acids from the begin-
ning ofconserved region C3, with the consensus ATP binding
site starting at amino acid 346 (Parker et al., 1986). Al-
though equal amounts of PKCTM385 and PKCTM310
plasmid were transfected, much less of the latter protein was
detected by Western blotting, suggesting that the regulatory
domain was rapidly degraded in the cytoplasm.
To determine whether the hinge region was entirely re-
sponsible for the subcellular distribution ofPKC7 and PKC8,
or ifportions of the catalytic domain also contribute to their
localization, we constructed an additional mutant that con-
sisted of the Al amino terminus fused to amino acid 385 of
PKCa (Fig. 1). This fusion protein, designated PKC14,
lacked the 75-amino acid segment defined in the above ex-
periments as being required for localization to the TI frac-
tion, but contained the remainder of the catalytic domain in-
tact. Surprisingly, this mutant was also tightly associated
with the TI pellet (Fig. 3), suggesting that a second region
present in the catalytic domain also participates in determin-
ing subcellular distribution .
Sincethe core ofthe catalytic domain is involved in cataly-
sis and is presumably unavailable for mediating localization
to the TI fraction, we felt that the extreme COOH terminus
was a likely candidate for this second binding region. We
therefore constructed a mutant similar to PKC14 but lacking
the last 62 amino acids at the COOH terminus (PKC16, see
Fig. 1). PKC16 yielded a protein of the expected molecular
mass when transcribed and translated in vitro, but we were
unable to detect it in either fraction following transfection
into COS cells, suggesting that it is extremely unstable (data
not shown) . Although the precise epitope for the anti-
catalytic domain mAb is not known, we were also unable to
detect PKC16 with a polyclonal antibody that recognizes
amino acids 520-525, indicating that our inability to detect
this mutant was not due to deletion of the antibody epitope
(data not shown). Based on the apparent instability of PKC-
TM310, which resides in the TS fraction, we believe that
PKC16 may also be unable to associate with the TI fraction
and is thus rapidly degraded in the cytoplasm.
Since a majority of the above mutants were found in a TI
pellet fraction, we considered the possibility that their ap-
parent distribution might be a result of an inherent insolubil-
ity caused by their altered conformation. To address this, we
transcribed and translated all the mutants in vitro and then
centrifuged the translation products at 200,000 g for 30 min.
Analysis of the supernatant and pellet fractions by elec-
trophoresis and fluorography revealed that the mutant pro-
teins remained in the supernatant (data not shown), suggest-
ing that their distribution in vivo is not due to inherent
insolubility.
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PKC Mutants in the TI Fraction Are Localized
to the Nuclear Envelope
To determine more precisely where the mutants in the TI
fraction were located, we subfractionated nuclei according
to the method of Kaufmann et al. (1983) . COS cells were
transfected with plasmids encoding the indicated proteins
and nuclei were isolated. Following treatment with DNAse
and RNAse, intranuclear proteins were separated from nu-
clear envelopes by extraction in buffer containing 1 .6 M
NaCl. Intranuclear proteins (1.6 M NaCI) and nuclear enve-
lope fractions were electrophoresed in triplicate and ana-
lyzed by Western blotting using either PKC antibodies (Fig.
4 a), anti-lamin B antisera (Fig. 4 b), or antisera to a 38-kD
nucleolar protein (Fig. 4 c) that is expected to be in the high
salt extract (Fields et al., 1986). The five mutant PKC pro-
teins found in the TI fraction (see Fig. 3) were localized al-
most entirely to the nuclear envelope fraction (Fig. 4 a; data
not shown for PKC7). Small amounts were detected in the
1.6 M NaCl (Fig. 4 a) and DNAse/RNAse extracts (data not
shown) . The 38-kD nucleolar protein was predominantly in
the 1.6 M NaCl extract (Fig. 4 c), whereas laminB was con-
sistently found in both the intranuclear and nuclear envelope
fractions (Fig. 4 b). Neither lamin B nor p38 were detected
in the postnuclear supernatant, and only residual levels were
found in the DNÁse/RNAse extract (data not shown) . Thus,
the PKC mutants found in the TI fraction were localized pri-
marily to the nuclear envelope.
Immunostaining ofCOS CellsExpressing
PKC Mutants
To confirm the results of biochemical fractionation and
Western blotting, we examined the subcellular distribution
of the PKC mutants by indirect immunofluorescence. As
shown in Fig. 5, COS cells transiently transfected with
PKC7, PKC8, PKCA12-253, and PKC14 displayed intense
perinuclear and nuclear staining with little or no staining in
the cytoplasm. Staining was not observed when the primary
antibody was omitted from the procedure (data not shown),
and nuclear staining was never seen in cells expressing wild-
type PKCa in the absence of PDBu (see below) . Some cells
expressing PKCTM385 occasionally yielded perinuclear
staining only, whereas in others the entire nucleus was
stained. However, the distribution of PKCTM385 was indis-
tinguishable from the other mutants when examined by sub-
cellular fractionation and Western blotting (Fig. 4). PKCI
and PKC2 yielded cytoplasmic and perinuclear staining that
was clearly distinct from that observed for the nuclear enve-
lope-localized mutants (data not shown) and was indistin-
guishable from that detected in cells expressing PKCa in the
absence of PDBu (see below). We have also observed nu-
clear localization ofthe truncation mutants in C2 myoblasts,
indicating that their ability to localize to the nucleus is not
restricted to COS cells (data not shown).
Held-type PKCa Is Translocated to the Nucleus in
Response to PDBu Stimulation
As stated above, previous studies have documentedthe phor-
bol ester-induced nuclear translocation of PKC in other cell
types. We wished to determine whether nuclear localization
of PKC truncation mutants (Figs. 4 and 5) reflected the pres-
868ence of a similar mechanism inCOS cells . Cells were tran-
siently transfected with plasmid encoding PKCce and the
subcellular distribution of the enzyme was examined by im-
munostaining at various time points following stimulation of
cells with PDBu . As shown in Fig . 6, untreated cells dis-
played cytoplasmic and perinuclear staining, whereas nuclei
were clearly unstained . An identical pattern of staining was
observed in cells treated with PDBu for 1 and 2 min (data
not shown) . However, after 5 min ofPDBu stimulation, im-
munostaining began to appear within nuclei . Nuclear stain-
ing was still apparent after 10 min and localization to a jux-
tanuclear position was also evident . After 20 min, staining
was almost entirely nuclear and juxtanuclear, and the cells
overexpressing PKC had begun to display a morphology
similar to that observed in other cell types after exposure to
phorbol ester (Housey et al ., 1988) . Nearly identical pat-
terns of staining were observed with anti-regulatory domain
(MC5) and anti-catalytic domain antibodies .
PKC7andPKC8Are Constitutively Activated
We wished to determine whetherPKC7 andPKC8 possessed
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Figure 4. PKC mutants reside in the nuclear en-
velope . COS cells in 10-cm dishes were transiently
transfected with 15 wg each of plasmids encoding
the indicated proteins . Intranuclear (1.6 M NaCl)
and nuclear envelope (envelope) fractions were pre-
pared (see Materials and Methods) and electropho-
resed in triplicate in 10% SDS-polyacrylamide gels,
followed by Western blotting. The blot a (48-h expo-
sure) was probed with a mixture of MC5 and anti-
catalytic domain mAbs, followed by 1251-labeled
anti-mouse secondaryantibody. b and cwere probed
with chicken antisera to lamin B and p38, respec-
tively, and bands were visualized as described in
Materials and Methods. Migration of molecular
weight standards is indicated at right ofa and b. This
experiment was performed three times with identi-
cal results .
kinase activity independently ofthe normally required cofac-
tors . As shown in Fig . 4, however, these mutants reside pri-
marily in the nuclear envelope andwe were unable to recon-
stitute kinase activity following their solubilization by
addition ofSDS . However, we found that til% of each mu-
tant protein was solubilized following lysis of cells in a
Dounce homogenizer in the presence of Triton X-100 (data
not shown) . Thus, plasmids encodingPKC7 and PKC8 were
transfected into COS cells and the mutant proteins present
in the soluble fraction were partially purified by DEAE
Sephacel chromatography. Fractions were assayed for kinase
activity towards a synthetic peptide substrate corresponding
to a region of the EGF receptor surrounding threonine 654 .
As presented in Table I, transfection with PKC7 and PKC8
resulted in an 8- to 11-fold increase, respectively, in co-
factor-independent kinase activity in the soluble fraction,
compared with transfection ofvector alone . PKC7 and PKC8
are therefore clearly constitutively activated, suggesting that
deletion of the regulatory domain results in a conformational
change in the catalytic domain . These data are consistent
with a previous study in which deletion of a portion of the
regulatory domains ofPKCa andPKCO was found to induce
869Figure 5 . Immunostaining ofCOS cells expressing nuclear envelope-localized PKCmutants . COS cells in 35-mm dishes were transiently
transfected with 5Ag each ofthe desired plasmids, as indicated at left . Cells were fixedand stained using theMC5 (PKC7, PKC8,PKC412-
253, andPKC-TM385) or anti-catalytic domain (PKC14) antibodies as described in Materialsand Methods . Two representative fields for
each mutant are shown, with the corresponding phase contrast photograph shown at right of each fluorescent image . Immunostaining of
each mutant was performed at least three times, and in some cases up to eight times, with identical results.
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￿
870Figure 6. Wild-typePKCa is translocated to the nucleus following PDBu treatment . COS cells in 35-mm dishes were transiently transfected
with 5 tig each ofplasmid encodingPKCa . 48 h after transfection, PDBu was added for the indicated lengths oftime at a final concentration
of 1 jug/nil . Duplicate dishes were prepared for each time point and immunostaining was performed as described in Materials and Methods
using either MC5 (top) or anti-catalytic domain (bottom) antibodies. The corresponding phase contrast photograph is shown below each
fluorescent image . This experiment was performed twice with identical results .
phorbol ester-independent kinase activity (Kaibuchi et al .,
￿
consensus ATP binding site lies between residues 346 and
1989) .
￿
368,we feel that the region responsible for localization to the
nuclear envelope is probably between amino acids 310 and
Discussion
The data presented here reveal that the subcellular distribu-
tion ofPKCcimay be mediated by regions outside the regula-
tory domain . These results indicate that activation ofthe en-
zyme by deletion of the regulatory domain induces a
conformational change in the hinge and catalytic domains,
exposing at least two separate regions of the primary se-
quence that have high affinity for one or more binding sites
present in the nuclear envelope .
The subcellular distributions of PKCTM385 and PKC-
TM310 indicate that the sequence between amino acids 310
and 385 encompasses a region that allows interaction ofPKC
with the nuclear envelope . This segment consists of the last
26 amino acids of the hinge region and the first 49 amino
acids ofthe catalytic domain (Parker et al ., 1986) . Since the
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Table I . PKC7andPKC8 Are Catalytically Active in
the Absence ofCofactors
871
COS cells in 10-cm dishes were transfected in quadruplicate with PCDM8,
PKC7, or PKC8 . The mutant proteins were partially purified from lysates as
described in Materials and Methods, and fractions were assayed for kinase
activity in the absence of calcium, phosphatidylserine, diacylglycerol, and
PDBu . Activities are expressed as pmol ofphosphate transferred tothepeptide
substrate permin permg ofprotein . The experiment was performed twice with
similar results .
Construct Kinase activity Relative activity
(pmol/min/mg)
pCDM8 29 1 .0
PKC7 234 8.1
PKC8 312 10.8346. However, we cannot at present rule out involvement of
residues lying in close proximity to the ATP binding site.
The sequence between amino acids 310 and 346 is of par-
ticular interest, since it is part of the largest region of non-
conserved sequence among the different PKC subtypes
(Coussens et al., 1986). The site for proteolysis by calpain
of the a, ß, and y subtypes of PKC has been mapped to this
region in vitro (Kishimoto et al., 1989) . Also, in cell types
that co-express two or more PKC subtypes, downregulation
of the various isoforms in response to chronic phorbol ester
treatment occurs at different rates, suggesting the possibility
of subtype-specific proteases in vivo (Ase et al., 1988; Hu-
ang et al ., 1989; Isakov et al., 1990). The presence of recep-
tors that interact specifically with the hingeregions of differ-
ent PKC subtypes would allow targeting of the activated
enzymes to precise locations within the cell, which would
in turn provide a means ofregulating their substrate specific-
ities, susceptibilities to proteolysis, or both .
The localization of PKC14 to the nuclear envelope was un-
expected, and suggested that a second region present in the
catalytic domain also interacts tightly with a component of
this fraction. Previous studies that concluded that proteolysis
in the hinge region resulted in a constitutively active, cyto-
plasmic catalytic domain would argueagainst any portion of
the catalytic domain-mediating association with the particu-
late fraction (Lee and Bell, 1986; Melloni et al ., 1985;
Mizuta et al., 1985). However, the possibility existed that a
second proteolytic cleavage might occur simultaneously
near the COOH terminus, resulting in removal of a small
COON-terminal fragment that has not previously been de-
tected. This possibility led us to construct PKC16, which was
similar to PKC14 but lacked the last 62 amino acids at the
COOH terminus. Although PKC16 yielded a protein of the
expected molecular mass when transcribed and translated in
vitro, we were unable to detect it following transfection into
COS cells, suggesting the possibility that it is indeed soluble
and rapidly degraded. This interpretation is consistent with
the inability of numerous investigators to detect a soluble
catalytic fragment by Western blotting (Kikkawa et al.,
1989; Ways et al., 1991), as well as with the apparent insta-
bility ofPKCTM310, suggesting that the individual domains
of PKC are targeted for rapid degradation once they are
released into the cytosol.
Although little is known aboutthe involvement of particu-
lar regions of the catalytic domain of PKC in catalysis,
Hanks et al. (1988) have identified highly conserved in-
dividual amino acids within the catalytic domains of both
serine/threonine and tyrosine protein kinases, suggesting
that they play fundamental roles in catalytic activity. The last
conserved residue in protein kinase catalytic domains is an
arginine, found at position 580 in PKCa. In many protein ki-
nases this residue lies very close to the COON terminus of
the molecule (Hanks et al., 1988), but members of the PKC
family have from 85 to 92 additional amino acids between
the arginine and the end of the protein, suggesting that the
extreme COOH terminus is involved in functions other than
catalysis (Coussens et al., 1986; Knopf et al., 1986; Ono et
al., 1988) . Thus, it is possible that this region interacts with
a receptor in the nuclear envelope. In contrast to the hinge
region, the COOH terminus is largely conserved among the
different PKC isoforms (Coussens et al., 1986; Knopf et al.,
1986; Ono et al., 1988), suggesting the possibility of both
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common and subtype-specific binding sites. The presence of
two separate regions in PKCa that are capable of interacting
with one or more receptors would provide the cell with an
additional mechanism by which to regulate the enzyme's
subcellular distribution, substrate specificity, or both.
The existence of receptors for activated PKC was sug-
gested by a recent study in which purified PKC was demon-
strated to bind in a saturable and specific manner to proteins
present in the TI fraction (Mochly-Rosen etal ., 1991). Bind-
ing was dependent upon the presence ofphosphatidylserine,
calcium, and diacylglycerol and was not inhibited by prein-
cubation with a peptide substrate. The authors concluded
that activation ofPKC resulted in exposure ofregions outside
the active site that bind via protein-protein interactions to
receptor molecules. Our results are consistent with this
model and reveal that a portion of the hinge region and at
leastone other segmentof the catalytic domain, possibly the
extreme COOH terminus, are responsible for this interac-
tion. Furthermore, the subcellular distribution ofthe consti-
tutive mutants indicates that the receptor(s) resides in the
nuclear envelope. Indeed, using a PKC8 bacterial fusion
protein as aprobe in a blotting assay similar to that described
by Mochly-Rosen et al. (1991), we have detected binding to
nuclear proteins of 30, 32, 55, and 100 kD.' Experiments
designed to map the regions of PKC required for interaction
with the various candidate receptors are in progress.
Despite original beliefs that PKC was primarily a plasma
membrane-localized enzyme, it has become clear in recent
years that translocation of these molecules to the nucleus
also occurs under certain conditions. In HL-60 cells PKCßn,
but not PKCa, was translocated to the nucleus after treat-
ment with bryostatin (Hocevar and Fields, 1991). This trans-
location resulted in increased phosphorylation of several nu-
clear envelope proteins, including lamin B. PKC0 has also
been detected in nuclei from rat liver (Rogue et al., 1990),
and phorbol ester treatment of NIH 3T3 fibroblasts resulted
in translocation of PKCce to the nucleus (Leach etal ., 1989).
In the latter study, it was demonstrated that PKCce co-frac-
tionated with lamin B, indicating that the enzyme was local-
ized to the nuclear envelope. Localization of constitutively
active mutants of PKC to the nuclear envelope is consistent
with translocation of wild-type PKC to the nuclear envelope
in response to knownactivators ofthe enzyme, and suggests
a common mechanism.
The PKC mutants found in the nuclear envelope remained
there following extraction with buffer containing 1.6 M
NaCl, suggesting a high-affinity interaction . This is also sug-
gested by the absence of PKC7 in the TS fraction. The
majority of the MARCKS protein is bound to the plasma
membrane (James and Olson, 1989a), and this association
is resistant to extraction with 0.5 M NaCl (Albert et al.,
1986). A nonmyristoylated mutant of the MARCKS protein
is primarily cytoplasmic (Graff et al., 1989), with a small
amount loosely associated with the membrane fraction.'
Thus, the myristoylated amino terminus of this protein con-
fers high-affinity binding to a component ofthe plasma mem-
brane. The lack of PKC7 in the TS fraction, where the wild-
type MARCKS protein is found, suggests that the PKCa
nuclear targeting signals, when exposed, are sufficient to
override the normal targeting information present in the
amino terminus of the MARCKS protein. The nuclear-local-
ized mutants described in this report, with theirhigh affinity
872for the nuclear envelope, will be valuable tools in the isola-
tion and characterization of the putative nuclear PKC re-
ceptor(s) .
It has recently been demonstrated that deletion ofportions
ofthe regulatory domains of PKCci and PKC0 is sufficientto
induce phorbol ester-independent kinase activity (Kaibuchi
et al., 1989) . However, the authors stated that their mutant
proteins were found mainly in the cytoplasmic fraction. Two
possible explanations may account for this apparent discrep-
ancy between their results and ours. First, the data support-
ing the cytoplasmic localization of their mutants was not
shown and it is not clear whether the nuclear fraction was
analyzed. It is therefore possible that a substantial amount
of these mutants were present in the nuclear fraction and
went undetected. In addition, their mutants were missing
only selected portions of the regulatory domain, as opposed
to PKC7 and PKC8, in which the entire regulatory domain
was deleted. We have foundthat a PKCci mutant that is miss-
ing the first 186 amino acids, therefore resemblinga number
of the previously described mutants, resides in both the nu-
clear envelope (N60%) and IS (-40%) fractions (data not
shown) . This suggests that localization to the nucleus is de-
pendent on the amount of regulatory domain deleted, and
that portions of the regulatory domain, when present in a
particular conformation, might exert a negative influence on
the interaction with the putative receptor(s). We believe that
the near complete localization ofmutants such as PKC8 and
PKC14 to the nuclear envelope reflects the "permanent ex-
posure of their nuclear targeting signals. In contrast, these
signals in the intact enzyme are probably masked by the
regulatory domain and are only exposed following a stimu-
lus-induced conformational change. In the holoenzyme, this
conformational change could be subject to reversal, medi-
ated by the regulatory domain, resulting in recovering of the
targeting signals and release from the nucleus.
The targeting of activated PKC mutants to the nucleus,
along with this and other reports demonstrating nuclear
translocation of wild-type PKC (Hocevar and Fields, 1991;
Leach et al., 1989 ; Rogue et al., 1990), suggest that the en-
zyme may exert its effects on nuclear events in a more direct
manner than was originally believed. Traditional models
depicted PKC as a component ofa signaling cascade that cul-
minated, at least in part, in altered transcription of target
genes (Bell, 1986; Kikkawa et al., 1989). However, our
results and those of others raise the possibility of direct
modification of nuclear regulatory proteins by PKC. In this
regard, we have found that PKC7 and PKC8 phosphorylate
the nuclear transcription factor myogenin on a threonine res-
idue in its DNA-binding domain in vivo, suppressing by
-95% its ability to activate transcription from the muscle
creatine kinase enhancer (Li, L., G. James, R. Heller-Harri-
son, M. Czech, and E. Olson, manuscript submitted for pub-
lication) . This same residue is phosphorylated by wild-type
PKCci in vitro, indicating that deletion of the regulatory do-
main does not alter the substrate specificity of PKC.
The existence of numerous PKC isoforms, many of which
are co-expressed in several cell types, has suggested that sub-
tle differences might exist in their subcellular distribution
and/or substrate specificities (Kikkawa et al., 1989). Indeed,
these expectations have been borne out in recent studies
(Hocevar and Fields, 1991; Kariya et al ., 1991). The findings
presented in this report provide the basis for a model by
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which these differences may be explained and suggest that
the effects of PKC activation on cellular processes might be
more complex than has previously been believed.
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